Company Overview
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Generates a return on equity of 19.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 91.1% CAGR over the past five years.
Trades at a P/E of 8.5, below the sector median of 24.8.
Maintains a net profit margin of 15.7%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $59.62M (+117.6% YoY); net profit $8.57M.
- Trailing 12 Months Year-on-year growth — revenue -95.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 91.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 91.11% |
| 1 Year: | -95.60% |
Stock Price Performance
| 1 Year: | -38.50% |
| 6 Months: | -48.71% |
| 3 Months: | -56.57% |
| 1 Month: | -5.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)35.76 · Neutral
P/E of 8.50 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 91.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 60.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPRO Spero Therapeutics, Inc. PHARMA | 1.19 | 8.50 | $69.30M | 0.00% | 11.92% | 19.17% | 91.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 3.81M | 67.00K | 172.00K | 696.00K | 169.00K | 51.00K | 38.00K | - | 2.11M | 708.00K | 247.00K | 896.00K | 1.08M | 223.00K | 269.00K | 218.00K | 140.00K | 114.00K | 65.00K | - | 5.11M | 11.80M | 3.05M | 39.66M | 258.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.67M | 14.16M | 10.38M | 8.25M | 7.80M |
| Operating Income | - | - | -7.91M | - | -7.60M | -10.16M | -9.97M | - | -10.82M | -9.97M | -10.94M | -5.70M | -13.65M | -17.98M | - | -22.82M | -18.48M | -19.02M | -19.40M | -18.54M | -22.52M | -30.21M | -26.08M | -11.83M | -14.23M | -12.89M | -1.93M | -13.98M | -19.06M | -18.59M | - | -14.56M | -2.36M | -7.33M | 31.41M | -7.54M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.56M | -2.36M | -7.33M | 31.41M | -7.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.87M | -1.70M | -7.38M | 31.78M | -7.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 290.00K | - | - | 0 | 261.00K | - |
| Net Income | -5.91M | -6.06M | -6.32M | -7.21M | -5.88M | -9.17M | -9.84M | -13.86M | -10.64M | -9.96M | -10.46M | -5.10M | -13.20M | -17.70M | - | -23.30M | -17.50M | -18.90M | -19.40M | -18.60M | -22.50M | -32.80M | -28.70M | -11.70M | -13.30M | -11.90M | -3.20M | -12.67M | -17.86M | -17.15M | - | -13.87M | -1.70M | -7.38M | 31.52M | -7.20M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.63 | -0.70 | -1.01 | -0.87 | -0.33 | -0.25 | -0.23 | -0.06 | -0.24 | -0.33 | -0.32 | - | -0.25 | -0.03 | -0.13 | 0.53 | -0.13 |
| R&D Expense | - | - | 6.00M | - | 6.00M | 7.46M | 6.91M | - | 8.93M | 7.37M | 8.46M | 9.53M | 12.03M | 18.50M | - | 20.44M | 15.66M | 17.71M | 18.40M | 14.46M | 14.44M | 16.97M | 8.17M | 7.36M | 8.98M | 9.51M | 16.39M | 17.33M | 23.73M | 26.86M | - | 13.61M | 10.67M | 8.60M | - | 2.91M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 335.00K | 1.98M | 3.97M | 4.74M | 258.00K | - | 48.58M | 96.73M | 27.40M | 59.62M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 79.15M | 69.95M | 99.88M | 52.46M |
| Operating Income | -13.33M | -33.22M | -41.73M | -42.81M | -63.22M | -79.11M | - | -30.57M | 26.79M | -72.48M | 7.16M |
| EBITDA | - | - | - | - | - | - | - | -42.94M | 27.15M | -72.48M | 7.16M |
| Interest Expense | - | - | - | - | - | - | 1.94M | 2.60M | 0 | - | - |
| Pretax Income | - | - | - | - | - | - | - | -46.41M | 25.40M | -68.57M | 8.83M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 2.60M | 0 | 261.00K |
| Net Income | -10.15M | -25.49M | -38.74M | -41.70M | -60.90M | -78.30M | - | -46.41M | 22.81M | -68.57M | 8.57M |
| Diluted EPS | - | - | - | - | - | - | - | -1.23 | 0.43 | -1.27 | 0.15 |
| R&D Expense | 11.12M | 26.33M | 32.87M | 33.88M | 65.78M | 67.00M | 64.53M | 47.59M | 51.44M | 96.76M | 38.47M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 13.77M | 93.48M | 129.01M | 106.10M | 153.45M | - | 124.80M | 182.39M | 110.54M | 68.92M |
| Current Assets | - | - | - | - | - | - | - | - | 113.57M | 131.21M | 107.28M | 67.29M |
| Cash & Equivalents | 256.00K | 5.69M | 10.31M | 87.29M | 34.08M | 29.73M | 85.21M | - | 109.11M | 76.33M | 52.89M | 40.27M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 1.08M | 50.70M | 52.48M | 25.39M |
| Total Liabilities | - | - | 7.41M | 8.52M | 13.15M | 31.53M | 21.41M | - | 48.87M | 75.50M | 64.42M | 9.90M |
| Current Liabilities | - | - | 6.92M | 8.16M | 12.32M | 26.66M | 14.34M | - | 21.65M | 37.15M | 49.07M | 8.87M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 6.65M | 5.54M | 4.30M | 2.90M |
| Total Equity | -6.11M | -18.55M | -45.44M | 84.60M | 115.50M | 74.57M | 132.04M | - | 75.93M | 106.89M | 46.12M | 59.02M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 52.46M | 53.00M | 54.59M | 56.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -28.96M | -39.11M | -39.62M | -50.02M | -85.87M | - | -7.73M | -32.99M | -23.44M | -12.62M |
| Investing Cash Flow | - | -830.00K | -27.00K | -83.16M | 29.53M | 10.47M | 7.67M | 33.81M | 0 | - | - |
| Financing Cash Flow | - | 34.41M | 116.11M | 69.52M | 16.14M | 130.88M | 84.05M | -29.55M | 221.00K | 0 | - |
| Capital Expenditure | -232.00K | -830.00K | -27.00K | -2.44M | -314.00K | -157.00K | - | - | - | - | - |
| Free Cash Flow | - | -29.79M | -39.14M | -42.06M | -50.33M | -86.03M | - | -7.73M | -32.99M | -23.44M | -12.62M |
| Net Change in Cash | - | - | - | - | - | - | - | -3.48M | -32.77M | -23.44M | -12.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -9,916.7% | -2,108.6% | -1,079.3% | -1,333.1% | -30,664.0% | - | -62.9% | 27.7% | -264.6% | 12.0% |
| Net Margin % | - | -7,609.3% | -1,957.7% | -1,051.4% | -1,284.3% | -30,348.8% | - | -95.5% | 23.6% | -250.3% | 14.4% |
| ROE % | 54.7% | 56.1% | -45.8% | -36.1% | -81.7% | -59.3% | - | -61.1% | 21.3% | -148.7% | 14.5% |
| ROCE % | - | -484.7% | -48.9% | -36.7% | -79.6% | -56.9% | - | -29.6% | 18.4% | -117.9% | 11.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GSK plc | 15.78% | 9.19M | $10.39M |
| 2 | Pfizer Inc | 4.06% | 2.36M | $2.67M |
| 3 | Vanguard Capital Management LLC | 3.50% | 2.04M | $2.30M |
| 4 | Renaissance Technologies, LLC | 1.63% | 947.90K | $1.07M |
| 5 | Alphabet Inc. | 1.53% | 889.98K | $1.01M |
| 6 | Susquehanna International Group, LLP | 1.30% | 759.29K | $858.00K |
| 7 | Blackrock Inc. | 1.02% | 594.40K | $671.68K |
| 8 | Geode Capital Management, LLC | 0.97% | 566.33K | $639.95K |
| 9 | Raymond James Financial, Inc. | 0.90% | 521.71K | $589.53K |
| 10 | Two Sigma Investments, LP | 0.66% | 382.81K | $432.58K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SPRO
New employees get stock awards at Spero, unlocking from 2027 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNZnBUemhOWEhSOEphN29SQTFkcXZuZlBkZ2FBOUJ3ZHZmWWk0b3VaNGNuSlFiRXhBblpwVm9LeVpXUDhfSFZWRU9UaWE1QXJhdVVfdHFLN1JYeWg0dzV1ZWp6M18zQUZ4Ql90UU9veWhPZEx6eFI4SmdRb0d4VlA1bGJMa01ybGxLYlBMU0…
$SPRO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOdEpRa0Q3d3I1ckdGMnk0WmRadWYtTExoSXljUHdTWDV3bEd1bEdobDB5ejRCdFpkNEhIaENTQl83cThtYWtQVERnLXM3ZmtIOFNQMXFCZmswSjBGT0cxRXpGMm11UmN4RGMwVEl6R21MTG15UkRxb2drNFhteUNlOTdGYU43LXJ0RkZyej…
Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQSzVIUmVVLWZQTGFOaVhxNnVBMWhHSGp1OHA3aGEyTERrR1NUYWR2YlZMdW1EaURQdXkwUjlLVFhDVjl6NWxsblloMElkQlJOdTA2WWNRV1BxNW1TSXdqTjJuVVZiZWFzdW9PQU4tUE5zR0x1T1BfQXZlck5pWkZWTm1aT0tyamlsbllnVE…
SPRO - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4tS2xyU0xfTU1TaXUyS1g1YXk3bXpOcE1UWnZBQkE2MC0ybzNDak0yTUo3X21JR3RudktMTE5LUFF5LWJiOEE?oc=5" target="_blank">SPRO</a> <font color="#6f6f6f">Finviz</font>…
SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9PNG1kdWFfb2RsTl9mZ0hXODNxbmJ4ZWU0cGdvLWgxdlhlOXE0UWpWc1BmOHNmaVotQ1EyOVJKY3B1T3BFdVZ3d2ZlY0wwaExHS1BsQS1SWEdFWElPc3JZYlBmSjNidHQ1d293Snk5dmZyOXRPWUZFZkpsczVGSGM?oc=5" target="_bla…
A biotech CEO will speak in New York Sept. 15. Spero will stream it. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxORG1qT19BR0Y4M0ZJYWhoTU90MHhzRThmaWozWUtDOXRkTXl4LWZXVzJNT3J5ZElYUkU0SkwzTkFwc3ZuQmUzeTZCYU04MTBxRHpSYlZiR2hkUlNNTWo4TnpGc1lVN0x6UGl5YmJibEtXUnJFRkh6TVIyd1NYWElhNDA1X1J2Y2tjbWRVd0…
SPRO — Frequently Asked Questions
What is the current share price of Spero Therapeutics, Inc. (SPRO)?
As of 2026-09-19 21:16 PDT, Spero Therapeutics, Inc. (SPRO) trades at $1.19 on NasdaqGS. Its 52-week range is $1.15 to $2.98.
What is the market capitalisation of SPRO?
Spero Therapeutics, Inc. (SPRO) has a market capitalisation of $69.30M on NasdaqGS.
What is the P/E ratio of SPRO?
SPRO trades at a trailing price-to-earnings (P/E) ratio of 8.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.49.
What is the return on equity (ROE) of SPRO?
SPRO has a return on equity (ROE) of 19.17%. Its return on capital employed (ROCE) is 11.92%.
Is SPRO a good stock to buy?
This page provides a data-driven analysis of Spero Therapeutics, Inc. (SPRO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.